Pierre Fabre Laboratories Acquires Vertical Bio And Its Innovative Targeted Therapy Candidate For Patients Suffering From Non-Small Cell Lung Cancer With Met Alteration
Acquiring Company
Pierre Fabre Laboratories
Acquired Company
Vertical Bio
Description
Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of a biotechnology company allows Pierre Fabre Laboratories to add VERT-002 to its oncology discovery pipeline. VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action, acting as a degrader of c-MET. This target is a known disease driver in patients suffering from Non-Small Cell Lung Cancer (NSCLC) with mutations or amplification of MET. Deal terms were not disclosed.
Who to call at Pierre Fabre Laboratories, and when
When Pierre Fabre Laboratories changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pierre Fabre Laboratories raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pierre Fabre Laboratories, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pierre Fabre Laboratories. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pierre Fabre Laboratories makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Vertical Bio?
Vertical Bio was acquired by Pierre Fabre Laboratories. The deal was reported on September 12, 2023. Pierre Fabre Laboratories is a leading French medical and beauty care company with over 4 decades of experience in innovation, development, manufacturing, and commercialization in oncology. Pierre Fabre Laboratories is privately held and operates in Manufacturing.
When did Pierre Fabre Laboratories acquire Vertical Bio?
Pierre Fabre Laboratories's acquisition of Vertical Bio was reported on September 12, 2023. Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Vertical Bio do?
Vertical Bio is a biotechnology company developing a novel antibody to treat certain forms of cancer. The company was founded by Versant Ventures and launched out of the firm's Ridgeline Discovery Engine based in Basel, Switzerland. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.